Category Archives: Medicine Wellness Health

Medicine Wellness Health

Fighting cancer: New PET-imaging method improves diagnosis and treatment of widespread carcinomas

A new nuclear medicine imaging method facilitates a more precise diagnosis of widespread carcinomas such as breast, colon, pancreas or lung cancer.

(Vienna, March 19, 2019) In fighting cancer an early and accurate diagnosis is crucial. A new nuclear medicine imaging method within the field of Positron emission tomography (PET) facilitates a more precise diagnosis of widespread carcinomas such as breast, colon, pancreas or lung cancer. Moreover, the novel imaging technique can combine the detection of the tumor with its treatment according to the patient“s individual needs. „By targeting a particular enzyme found on the membrane of cancer-associated fibroblasts we may achieve a better outcome than with the methods used so far,“ says Professor Uwe Haberkorn, expert of the European Association of Nuclear Medicine (EANM).

The leading part within the newly developed PET imaging concept is played by the so-called fibroblast activation protein (FAP). This enzyme is found abundantly on the membrane of Cancer-associated fibroblasts (CAFs). These cells are present in more than 90 percent of epithelial carcinomas, including for example pancreatic, colon and breast cancer. High occurence of FAP indicates a poor prognosis. However, although CAFs are involved in the growth and spreading of the tumor they are no cancer cells themselves. Since they are genetically more stable than cancer cells they are less likely to develop therapy resistance. „All these characteristics make FAP a promising target for nuclear medical diagnostic as well as therapeutic approaches,“ says EANM expert Prof. Uwe Haberkorn who developed the new imaging method together with his team in Heidelberg.

Outperforming the standard methods
PET imaging always requires that the patient be injected with a small amount of a radioactively labeled substance, a so-called tracer, by which biological processes such as the metabolism of tumor cells can be targeted and made visible through the imaging system. So far, the most commonly used tracer has been 18F-fluorodeoxyglucose (FDG), a radioactively-marked sugar, taken up by cells with high-energy consumptions such as cancer or the brain. However, as Prof. Haberkorn points out, the results achieved with FDG with regard to tumor uptake and image contrast are not always satisfactory.
Against this backdrop his team developed a novel tracer based on an FAP-specific enzyme inhibitor (FAPI), a small molecule that binds to the FAP by blocking its chemical reaction. The FAPI-tracer which is labeled with the radionuclide gallium-68 shows high uptake by the tumors but fast clearance by the healthy parts of the body. This results in high-contrast images due to very low binding to the surrounding healthy tissue in tumor patients, thus clearly outperforming FDG in important regions of metastatic disease such as the liver and the brain. The positive outcome has been repeatedly demonstrated by a number of preclinical and clinical studies.

Intertwining diagnosis and therapy
„Radiolabeled FAPIs allow for fast imaging with very high contrast in all tumors that contain a high amount of connective tissue cells,“ says Prof. Haberkorn. But there is even more to it: „FAPIs, as opposed to FDG, can also be employed for treatment purposes. This is due to chemical properties allowing labeling not only with gallium-68, but also with radionuclides such as rhenium-188 (188Re), lead-212 (212Pb) or yttrium-90 (90Y) that can be used to destroy the tumor. That means, a theranostic approach – a tight intertwining of diagnosis and therapy taylored to the individual patient“s needs – seems feasible.“ FAPI-imaging is not even restriced to cancer since it can be applied to all processes that involve the remodelling of tissue. This makes it very likely that the technique will soon be used for diagnosing and treating non-cancerous conditions too, such as cardiovascular and rheumatic diseases as well as fibroses of the lung, the liver and the kidney. So far, the new tracer has been successfully applied to several hundreds of patients in a number of hospitals in Germany, and is currently being used for preclinical studies in the US and Japan. „FAPI-imaging has opened up a promising avenue for the detection and treatment of many malignant tumors and offers additional potential with respect to several other diseases,“ says Prof. Haberkorn.

Presseagentur für Medizinthemen

Contact
impressum health & science communication
Frank von Spee
Hohe Brücke 1
20459 Hamburg
Phone: 040 31786410
E-Mail: vonspee@impressum.de
Url: http://www.impressum.de

Medicine Wellness Health

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

clinical trial WATCH AF stating best in class measurement results with more than 96% accuracy.

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

Preventicus Smartwatch for stroke prevention

Jena, 15th March 2018. Using smartwatches in measuring important health data has been intensively discussed lately. Not only because of personal health data, but also discussing functional limitations and false positives results. The aim is clear – a smartwatch should not only stay a lifetime tool but contain medical grade applications, certified by a notified body. In relation, scientists from the German Center for Cardiovascular Research (DZHK) at the University Medical Center Greifswald and scientists from the University Hospital Basel published the WATCH AF results, which conclude that smartwatches could be used to comfortably and regularly survey the heart rhythm of patients at increased risk, when using specific algorithms. Atrial fibrillation could be discovered earlier, subsequently leading to prompter diagnosis and therapy initiation for stroke prevention.

Atrial fibrillation (AF) is the most common cardiac arrhythmia with increasing incidence. Unfortunately, AF often is undetected and thus left untreated, as it often occurs as a seizure and does not necessarily cause any discomfort. Undetected and untreated AF increases the stroke risk five times. Approximately a third of ischemic strokes come along with atrial fibrillation. Hence, systematic screening for AF in risk populations, also utilizing smartphone camera or smartwatch PPG, is recommended by the European Heart Rhythm Association.

The prospective controlled WATCH AF trial investigated 672 participants with and without atrial fibrillation to proof, how accurate AF can be detected with a smartwatch utilizing the Preventicus application. For this purpose, the PPG sensor based heart rhythm recordings of the smartwatches were analyzed by the automatic algorithm of Preventicus for the presence of atrial fibrillation. The results were compared with cardiologists final diagnosis based on a mobile electrocardiogram (ECG) device in a blinded way. It showed that the smartwatch can detect atrial fibrillation at least as well and accurately as the mobile ECG. „It was particularly important that not too many false-positive findings were raised by the app. „says Prof. Marcus Dörr, one of the Investigators. „Because this would result in unnecessary investigations and high costs.“ The study also showed that repeated one-minute recordings are sufficient to reliably detect cardiac arrhythmias. In conclusion the results of the WATCH AF trial suggest that detection of AF using a commercially available smartwatch is in principle feasible, with very high diagnostic accuracy, when using the Preventicus application.

Currently, patients with an increased risk of atrial fibrillation receive a long-term ECG (Holte- ECG) that records the heart rhythm mostly for 24h, in dedicated situations up to 72h. If nothing is discovered during this period, one can theoretically stop following the guidelines to monitor the heart rhythm. If the risk is very high and Holter-ECG remains negative, small implantable event recorders behind the sternum can be used in selected cases. A smartwatch is comparatively cheap and theoretically can be purchased by anyone. It may therefore close the gap between the long-term ECG and an implanted device in the future.

Preventicus offers full service integrated care programs for screening, diagnosis and management of cardiovascular diseases, such as Atrial Fibrillation. Unique features of Preventicus are superior biosignal analytic algorithms – certified as a CE class IIa medical product, with high clinical evidence – enabling risk screening by smartphone or wearables. That enables users to carry out previously complex home-based check ups via their smartphones and maintain their own health through tailor-made preventive measures.

Company-Contact
Preventicus GmbH
Thomas Hübner
Goethestr. 3a
07743 Jena
Phone: +49 (0) 36 41 / 55 98 45-0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Press
Preventicus GmbH
Sylvie Mosig
Goethestr. 3a
07743 Jena
Phone: +49 (0) 36 41 / 55 98 45-0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Medicine Wellness Health

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

clinical trial WATCH AF stating best in class measurement results with more than 96% accuracy.

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

Preventicus Nightwatch

Jena, 15th March 2018. Using smartwatches in measuring important health data has been intensively discussed lately. Not only because of personal health data, but also discussing functional limitations and false positives results. The aim is clear – a smartwatch should not only stay a lifetime tool but contain medical grade applications, certified by a notified body. In relation, scientists from the German Center for Cardiovascular Research (DZHK) at the University Medical Center Greifswald and scientists from the University Hospital Basel published the WATCH AF results, which conclude that smartwatches could be used to comfortably and regularly survey the heart rhythm of patients at increased risk, when using specific algorithms. Atrial fibrillation could be discovered earlier, subsequently leading to prompter diagnosis and therapy initiation for stroke prevention.

Atrial fibrillation (AF) is the most common cardiac arrhythmia with increasing incidence. Unfortunately, AF often is undetected and thus left untreated, as it often occurs as a seizure and does not necessarily cause any discomfort. Undetected and untreated AF increases the stroke risk five times. Approximately a third of ischemic strokes come along with atrial fibrillation. Hence, systematic screening for AF in risk populations, also utilizing smartphone camera or smartwatch PPG, is recommended by the European Heart Rhythm Association.

The prospective controlled WATCH AF trial investigated 672 participants with and without atrial fibrillation to proof, how accurate AF can be detected with a smartwatch utilizing the Preventicus application. For this purpose, the PPG sensor based heart rhythm recordings of the smartwatches were analyzed by the automatic algorithm of Preventicus for the presence of atrial fibrillation. The results were compared with cardiologists final diagnosis based on a mobile electrocardiogram (ECG) device in a blinded way. It showed that the smartwatch can detect atrial fibrillation at least as well and accurately as the mobile ECG. „It was particularly important that not too many false-positive findings were raised by the app. „says Prof. Marcus Dörr, one of the Investigators. „Because this would result in unnecessary investigations and high costs.“

The study also showed that repeated one-minute recordings are sufficient to reliably detect cardiac arrhythmias. In conclusion the results of the WATCH AF trial suggest that detection of AF using a commercially available smartwatch is in principle feasible, with very high diagnostic accuracy, when using the Preventicus application.

Currently, patients with an increased risk of atrial fibrillation receive a long-term ECG (Holte- ECG) that records the heart rhythm mostly for 24h, in dedicated situations up to 72h. If nothing is discovered during this period, one can theoretically stop following the guidelines to monitor the heart rhythm. If the risk is very high and Holter-ECG remains negative, small implantable event recorders behind the sternum can be used in selected cases. A smartwatch is comparatively cheap and theoretically can be purchased by anyone. It may therefore close the gap between the long-term ECG and an implanted device in the future.

The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. Dörr M, Nohturfft V, Brasier N, Bosshard E, Djurdjevic A, Gross S, Raichle CJ, Rhinisperger M, Stöckli R, Eckstein J. JACC Clin Electrophysiol. 2019 Feb;5(2): 199-208.. DOI:10.1016/j.jacep.2018.10.006.

Preventicus offers full service integrated care programs for screening, diagnosis and management of cardiovascular diseases, such as Atrial Fibrillation. Unique features of Preventicus are superior biosignal-analytic algorithms – certified as a CE class IIa medical product, with high clinical evidence – enabling risk screening by smartphone or wearables. That enables users to carry out previously complex home-based check-ups via their smartphones and maintain their own health through tailor-made preventive measures.

Company-Contact
Preventicus GmbH
Thomas Hübner
Goethestr. 3b
07743 Jena
Phone: +49 (0) 69 9072013 0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Press
Preventicus GmbH
Sylvie Mosig
Goethestr. 3b
07743 Jena
Phone: +49 (0) 69 9072013 0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Medicine Wellness Health

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

clinical trial WATCH AF stating best in class measurement results with more than 96% accuracy.

Atrial fibrillation can be detected correctly by commercially available smartwatches using Preventicus application

Preventicus

Jena, 15th March 2018. Using smartwatches in measuring important health data has been intensively discussed lately. Not only because of personal health data, but also discussing functional limitations and false positives results. The aim is clear – a smartwatch should not only stay a lifetime tool but contain medical grade applications, certified by a notified body. In relation, scientists from the German Center for Cardiovascular Research (DZHK) at the University Medical Center Greifswald and scientists from the University Hospital Basel published the WATCH AF results, which conclude that smartwatches could be used to comfortably and regularly survey the heart rhythm of patients at increased risk, when using specific algorithms. Atrial fibrillation could be discovered earlier, subsequently leading to prompter diagnosis and therapy initiation for stroke prevention.

Atrial fibrillation (AF) is the most common cardiac arrhythmia with increasing incidence. Unfortunately, AF often is undetected and thus left untreated, as it often occurs as a seizure and does not necessarily cause any discomfort. Undetected and untreated AF increases the stroke risk five times. Approximately a third of ischemic strokes come along with atrial fibrillation. Hence, systematic screening for AF in risk populations, also utilizing smartphone camera or smartwatch PPG, is recommended by the European Heart Rhythm Association.

The prospective controlled WATCH AF trial investigated 672 participants with and without atrial fibrillation to proof, how accurate AF can be detected with a smartwatch utilizing the Preventicus application. For this purpose, the PPG sensor based heart rhythm recordings of the smartwatches were analyzed by the automatic algorithm of Preventicus for the presence of atrial fibrillation. The results were compared with cardiologists final diagnosis based on a mobile electrocardiogram (ECG) device in a blinded way. It showed that the smartwatch can detect atrial fibrillation at least as well and accurately as the mobile ECG. „It was particularly important that not too many false-positive findings were raised by the app. „says Prof. Marcus Dörr, one of the Investigators. „Because this would result in unnecessary investigations and high costs.“

The study also showed that repeated one-minute recordings are sufficient to reliably detect cardiac arrhythmias. In conclusion the results of the WATCH AF trial suggest that detection of AF using a commercially available smartwatch is in principle feasible, with very high diagnostic accuracy, when using the Preventicus application.

Currently, patients with an increased risk of atrial fibrillation receive a long-term ECG (Holte- ECG) that records the heart rhythm mostly for 24h, in dedicated situations up to 72h. If nothing is discovered during this period, one can theoretically stop following the guidelines to monitor the heart rhythm. If the risk is very high and Holter-ECG remains negative, small implantable event recorders behind the sternum can be used in selected cases. A smartwatch is comparatively cheap and theoretically can be purchased by anyone. It may therefore close the gap between the long-term ECG and an implanted device in the future.

Preventicus offers full service integrated care programs for screening, diagnosis and management of cardiovascular diseases, such as Atrial Fibrillation. Unique features of Preventicus are superior biosignal-analytic algorithms – certified as a CE class IIa medical product, with high clinical evidence – enabling risk screening by smartphone or wearables. That enables users to carry out previously complex home-based check-ups via their smartphones and maintain their own health through tailor-made preventive measures.

Company-Contact
Preventicus GmbH
Thomas Hübner
Goethestr. 3b
07743 Jena
Phone: +49 (0) 69 9072013 0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Press
Preventicus GmbH
Sylvie Mosig
Goethestr. 3b
07743 Jena
Phone: +49 (0) 69 9072013 0
E-Mail: info@preventicus.com
Url: http://www.preventicus.com

Medicine Wellness Health

Maisense announces CE Mark Approval of ECG Atrial Fibrillation Detection for cardiovascular monitor

Maisense announces CE Mark Approval of ECG Atrial Fibrillation Detection for cardiovascular monitor

Maisense’s award winning Freescan solution (Source: © Maisense)

First all-in-one Personal Cardiovascular Monitor and AI-based Stroke Prevention to enable early detection of key factors indicating stroke risk

Hsinchu, Taiwan March 15th, 2019 – Maisense, an innovative startup, devotes itself to stroke prevention, announced today it has received CE Mark clearance for its ECG Atrial Fibrillation and Arrhythmia (Tachycardia and Bradycardia) detection. The award winning solution already received the CE Mark for cuff-less blood pressure monitoring in 2015. The approval makes Maisense’s Freescan the first CE approved cardiovascular monitor which combines cuffless blood pressure measurement and ECG Atrial Fibrillation Detection in a single measurement. Freescan is particularly user friendly while providing very precise results.

In 2015, Maisense launched Freescan, the world first pocket-sized cuff-less blood pressure monitor, with CE class II medical certification. Freescan has won several recognitions worldwide: 2016 Top 10 innovations in Arab Health Expo, and 2018 top 10 health App at MEDICA App Competition in Germany. Maisense also won the 2017 Taiwan top 10 coolest innovative startups award.

„It is a significant achievement of Freescan to obtain the CE Mark Approval for ECG Atrial Fibrillation (AFib) detection. This empowers those health-conscious individuals in Europe and other countries (which recognize CE Mark) to track the signs of cardiovascular diseases at home, because early recognition is key to reducing the risk for strokes and other cardiovascular diseases,“ said Bach Chen, CEO of Maisense.

According to World Health Organization (WHO)“s report in May 2018, stroke is the second leading cause of deaths globally after ischemic heart disease. Of the 56.9 million deaths in 2016, almost 6 million died in stroke, about 10% of all deaths. Since up to 80% of stroke are preventable, „It is Maisense“s mission to help people to enjoy better quality of life. We started with stroke prevention by detecting the top 3 risk factors of stroke-arterial stiffness, atrial fibrillation and hypertension,“ said Andrew Chang, chairman of Maisense.

Not only does Maisense improve the processes of measurement through the pocket-sized „Freescan“ device, but it also enables individuals to easily manage their own health by monitoring and analyzing their own vital signs using the intelligent „myFreescan“ App. Users can observe many features on myFreescan, such as trend view for historical blood pressure measurements, rPWV (radial pulse wave velocity for arterial stiffness), AFib/ arrhythmia screening, and ECG/pulse waveform viewing.
Freescan“s clinical validation on AFib detection was finished in the Chang-Gung Memorial Hospital, Keelung, Taiwan with sensitivity of 96.72% and specificity of 99.06%. The result will be presented at EHRA (European Heart Rhythm Association) in Lisbon, Portugal on March 17th~ 19th 2019 by the topic „Clinical Validation of a Portable Cardiovascular monitor for Atrial Fibrillation Detection“.

Maisense is also growing its channel and is actively looking for distributors in the European Union. In Germany, Maisense is excited to have formed a partnership with the well renowned TITAN Commerce and appPeople. TITAN Commerce is a leading distributor for Bio-/Neurofeedback, sportswear technology and wearables based in Germany. appPeople provides worldwide progressive impulses in the field of telemedicine. Freescan is also available in Germany at Mindtec ( https://goo.gl/VmBsR7) and ME Health CHECK ( https://goo.gl/JGZjZo).

About TITAN Commerce
TITAN Commerce“s wide product range includes state-of-the-art biotechnology, wearables and professional Sportswear technologies from various well-known biofeedback, neurofeedback and wearable manufacturers. The goal of TITAN Commerce is to provide end-customer with the most technically innovative products to help them to deal with their daily impact of external influences such as stress, exhaustion, concentration and attention deficits. For more information, please visit: http://www.titan-commerce.com/de/

About appPeople
Founded in 2011, appPeople GmbH develops and distributes mobile applications and medical devices. The innovative products enable the regular collection of relevant health parameters, helping to better assess treatment outcomes and improve users‘ quality of life. The dynamically growing company works with partners in Europe and Asia and is one of the most successful and creative names in its field. For more information, please visit: http://www.apppeople.de/en/start.html

About Maisense:
Maisense is an innovative startup engaging in non-invasive cardiovascular monitor for personal use and artificial intelligence software for stroke prevention including AFib/arrhythmia/artery stiffness detection for professional physician use. Founded in 2012, Maisense was granted the award for „Best Investment Potential“ by Taiwan“s Ministry of Economic Affairs. Maisense“s Freescan is the world first cuff-less blood pressure monitor measuring directly from wrist pulse and it has received EU CE medical certification. It has been honored with the 2015 National Innovation Award in Taiwan, as well as ranking second among the Top 10 Innovative Health Products at the Arab Health 2016 fair in Dubai. In 2017, it has received the „Taiwan top 10 coolest innovative startups award“ from the Ministry of Science and Tech in Taiwan. For more information, visit www.maisense.com

Company-Contact
Pressoffice Maisense
Wibke Sonderkamp
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.40
E-Mail: wibke@gcpr.net
Url: http://www.maisense.com/en/

Press
Pressoffice Maisense
Laura Lehmann
Münchner Str. 14
85748 Garching bei München
Phone: +49.89.360363.52
E-Mail: laura@gcpr.net
Url: https://www.gcpr.de/

Medicine Wellness Health

New Fitness App Mighty Empowers Women To Fight Against Harassment; Celebrates Women’s Day With Special Program

New Fitness App Mighty Empowers Women To Fight Against Harassment;   Celebrates Women

Berlin, embargoed for INTERNATIONAL WOMEN’S DAY, March 8th, 2019 @ 7:30AM EST

2019’s newcomer app Mighty („No. 1 New App We Love“ by Apple), a self-defense fitness program for women, just debuted for iPhone. Mighty pairs daily fitness training with powerful self-defense techniques, so users can learn to protect themselves while working out. From March 8th to 14th Mighty is offering 50% off their entire monthly, yearly and lifetime programs in celebration of International Women’s Day and female empowerment worldwide.

WATCH VIDEO: https://www.mightyselfdefense.com/press/en

„Mighty is about living life on your own terms!“ says Nadja Wohlleben, self-defense trainer and co-creator of Mighty. „Knowing how to defend yourself is extremely empowering, and we wanted to make that knowledge as widely available as possible.“ The Berlin-based Taekwondo black belt has over 20 years of martial arts experience, and has taught hundreds of women and girls how to fight back against harassment and sexual violence.

During her years of teaching, Wohlleben continued to run into the same problem. After her weekend workshops, students kept asking about ways to practice at home. „Unfortunately, there was never anything I could truly recommend.“

Andreas Pursian, a senior software developer discovered the same problem when signing up with his wife and daughter for a neighborhood self-defense class. „I was surprised that nobody had brought this critical topic to a compelling digital video format yet.“ Pursian is somewhat of a video app pioneer. His last app Hyper, a curated video magazine, was named „Best of the Year“ by Apple three times and earned widespread press acclaim (The Verge: „Sleek and of the moment in the best way possible“; The Boston Globe: „Leaps and bounds better than any other video app“).

The two began collaborating on Mighty in 2018. The team quickly grew to include designers, videographers, and a crew of self-defense experts and coaches-including the seven Mighty trainers that guide users through the 300+ video lessons and workouts in the app.

Mighty’s unique program follows a holistic approach that places equal emphasis on mental empowerment and physical skills. Users learn effective boundary setting, awareness, and verbal techniques-plus how to react quickly to threats with powerful strikes and badass escape moves. „Our vision is a world in which no woman is afraid to stand up for herself,“ says Wohlleben, „whether that“s in the workplace, the streets or in their relationships.“

PRESS KIT: https://www.mightyselfdefense.com/press/en
DOWNLOAD APP: https://apple.co/2Efy5Xa

————————–
About: Mighty was created in Berlin, the city that just declared International Women“s Day a public holiday. The app is available for iPhone only but the team is working to bring it to more platforms this year.

Contact: press@mightyselfdefense.com, +49 177 3726918

Mighty is operated by release2 GmbH – iOS design & development studio

Company-Contact
release2 GmbH
Markus Gilles
Manteuffelstr. 61
10999 Berlin
Phone: 01773726918
E-Mail: hello@release2.de
Url: http://www.mightyselfdefense.com

Press
Mighty – Self Defense Fitness
Markus Gilles
Manteuffelstr. 61
10999 Berlin
Phone: 01773726918
E-Mail: press@mightyselfdefense.com.de
Url: http://www.mightyselfdefense.com

Medicine Wellness Health

Study Shows Cost-Saving Potential of CytoSorb Therapy in Cardiac Surgery

A health economic cost analysis of acute endocarditis patients treated with CytoSorb during
open heart surgery suggests significant saving opportunities.
The analysis is based on a 2017 published study of Prof. Dr. med. Karl Träger.

Study Shows Cost-Saving Potential of CytoSorb Therapy in Cardiac Surgery

Munich, February 21, 2019 – CytoSorbents, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the outcomes of a recent analysis at the 48th Annual Meeting of the German Society of Thorax, Heart and Vascular Surgery, 16-19 February, 2019, in Wiesbaden, Germany. This first health economic analysis concerning the study1, entitled „Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass – a case series,“ was conducted together with Prof. Dr. med. Karl Träger, Department of Cardiac Anesthesiology, University Hospital Ulm, Ulm, Germany.

The objectives of the analysis were to estimate the mean costs per patient of introducing CytoSorb as an adjuvant therapy compared to standard treatment without CytoSorb in the treatment of acute infective endocarditis from a German hospital perspective using intensive care unit (ICU) length of stay (LoS).

CytoSorb was used intraoperatively in patients with acute infective endocarditis (n=39). The control group was a historic cohort from the same hospital (n=28). Treated patients were overall sicker (median EuroScore II: 12.8 vs 10.2, p=0.03). Despite the low number of patients, the difference in the median ICU LoS of 2.5 days (7.5 vs. 5 days, p=0.059) suggests a reduction in the LoS.

A bootstrap analysis with 1,000 samples with 100 observations each (50:50) was performed based on the individual ICU LoS data of these patients from the university hospital. A probabilistic multivariable analysis performed by Monte Carlo simulations and a one-way sensitivity analysis to test for several cost driving variables were used to analyze the robustness of the result. Treatment with CytoSorb resulted in a median reduction in ICU LOS of 2.33 days (IQR: 1.5-3) of all treated patients according to the bootstrap analysis, a conservative estimate compared to the 2.5 days observed in the study.

The model estimated average savings of 1,660EUR per patient for the hospital with an 82% probability of being cost-saving even without any additional device-specific reimbursement. These savings rise to an average amount of 3,211EUR with a probability of 99% of being cost-saving when there is full reimbursement of the CytoSorb device costs (Fig. 1).

The costs of the ICU stay have the highest impact on the level of cost savings. However, CytoSorb remains cost saving irrespective of variations in all cost driving variables. The reduction in ICU LoS also opens the door to additional revenue for the hospital by being able to operate more patients since engaged ICU beds are often a bottleneck of a highly efficient cardiac surgery program.

Dr. Christian Steiner, Managing Director CytoSorbents Europe, said, „We strongly believe that the introduction of CytoSorb therapy has the potential to help many patients with different diseases. We are working very hard to build the necessary clinical data and evidence that it can be introduced in therapy guidelines soon.“

Prof. Dr.med. Karl Träger said, „We are using the CytoSorb therapy for several years now in different indications. The intraoperative application of CytoSorb for the treatment of acute infective endocarditis suggests a cost-saving impact, which is a great addition to the positive clinical effects we see.“

1Träger et al. IJAO. 2017; 40(5): 240-249

CytoSorb is a registered trademark of CytoSorbents Corporation.

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in new technologies and therapies in intelligent blood purification. CytoSorbents Europe GmbH is a hundred percent daughter company of CytoSorbents Corporation and coordinates the introduction and commercialization of CytoSorbents products worldwide.
Its flagship product, CytoSorb® is the first specifically-approved extracorporeal cytokine absorber in the European Union and it is distributed in more than 50 countries worldwide. CytoSorb was designed to reduce the „cytokine storm“ or „cytokine release syndrome,“ which is a major element of the deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. CytoSorbents“ purification technologies are based on biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. CytoSorb has been used in more than 56,000 human treatments to date.

CytoSorbents technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others.

For more information, please visit the Company“s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Company-Contact
CytoSorbents
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Press
Lucy Turpin Communications GmbH
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Medicine Wellness Health

Lucy Turpin Communications Wins MedTech Client

CytoSorbents“ flagship product lowers the risks caused by life threatening inflammation

Lucy Turpin Communications Wins MedTech Client

Munich, February 20, 2019 – CytoSorbents, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has selected Lucy Turpin Communications (LTC) as its agency of record for Europe.

LTC will be responsible for a comprehensive range of marketing services, including marketing communications, Social Media activities, etc. The agency will be working in close collaboration, both strategically and within various campaigns with Dr. Christian Steiner, Senior SVP Sales & Marketing of CytoSorbents Corporation and Managing Director of CytoSorbents Europe GmbH. The agency will be establishing and professionalizing the company“s marketing activities. Apart from making the CytoSorb therapy visible in the healthcare ecosystem, LTC will be positioning CytoSorbents as a relevant player with a solution for the European medical community.

CytoSorbents“ flagship product, CytoSorb©, is a blood purifying therapy – based on an extracorporeal cytokine adsorber – designed for cardiac surgeons, cardiologists and intensive care specialists. These doctors aim to reduce the risks of deadly inflammation, known as „cytokine-release syndrome“ in critically-ill patients. CytoSorb is designed to lower the probability and harmful impact of an immune over-reaction in severe acute diseases such as septic shock, which can lead to life-threatening multiple organ failure if left untreated.

The purification technology is based on a cartridge containing biocompatible and highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. Each of these spherical beads is approximately the size of a grain of salt and synthesized to contain millions of optimally-sized pores and channels. These pores and channels collectively have a massive surface area that enable the bead to behave like a tiny sponge to safely bind and effectively remove a broad range of inflammatory and toxic substances from whole blood.

Dr. Christian Steiner, SVP Sales & Marketing and Managing Director CytoSorbents Europe, said, „We decided on LTC because of its successful medical industry practice, compelling reputation and obvious professional approach. There was an immediate understanding of our vision that the broad introduction of CytoSorb therapy will potentially create a disruptive change of critical care medicine.“

„It is very exciting for us to be able to contribute to bringing CytoSorbents“ truly innovative solution to the European healthcare market,“ said Thomas Hahnel, General Manager of LTC. „Our goal is to create a critical mass of awareness for the therapy and its benefits.“

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in new technologies and therapies in intelligent blood purification. CytoSorbents Europe GmbH is a hundred percent daughter company of CytoSorbents Corporation and coordinates the introduction and commercialization of CytoSorbents products worldwide.
Its flagship product, CytoSorb® is the first specifically-approved extracorporeal cytokine absorber in the European Union and it is distributed in more than 50 countries worldwide. CytoSorb was designed to reduce the „cytokine storm“ or „cytokine release syndrome,“ which is a major element of the deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. CytoSorbents“ purification technologies are based on biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. CytoSorb has been used in more than 56,000 human treatments to date.

CytoSorbents technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others.

For more information, please visit the Company“s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

About Lucy Turpin Communications:
Founded in 1995, Lucy Turpin Communications is a leading PR, Social Media and Marketing Communications agency specialized in the DACH market ecosystem. Its B2B and B2C clients – most often positioned in High Tech sectors such as ITC, Electronics, Life Sciences, Clean Tech and Industrial Solutions – reap valuable benefits from LTC“s strategic approach, creativity, experience and passion for communications. www.lucyturpin.com/en; Twitter: @LTCComms

Company-Contact
CytoSorbents
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: CytoSorbents@lucyturpin.com
Url: https://www.cytosorbents.com/

Press
Lucy Turpin Communications
Thomas Hahnel
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -10
E-Mail: CytoSorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Medicine Wellness Health

Study Shows Significant Positive Effects of CytoSorb Therapy for Septic Shock Patients

Treatment with CytoSorb for cytokine removal in early septic shock shows improvement of clinical condition and inflammatory response

Study Shows Significant Positive Effects of CytoSorb Therapy for Septic Shock Patients

Berlin, Germany, February 14, 2019 – CytoSorbents Europe GmbH announces the publication of positive results of a randomized, controlled pilot study, proving a significant stabilization of the cardio-vascular system of patients who suffered from septic shock and have been treated with CytoSorb® as an early standalone (meaning without combined renal replacement) therapy for extracorporeal cytokine removal.

CytoSorb therapy is based on the first specifically-approved extracorporeal cytokine adsorber – CytoSorb 300 – marketed in the European Union and was designed to reduce the „cytokine storm“ or „cytokine release syndrome“ which is a major contributing factor in deadly inflammation. It is based on a cartridge containing biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood.

The pilot study will be published in the February issue of the Journal of Critical Care (49: 172-178) and can be accessed as an Epub under this link. It was authored by a medical team with the Department of Anesthesiology and Intensive Therapy of the University Szeged in Hungary, led by Professor Zsolt Molnar, a leading expert in the research and treatment of sepsis and septic shock. The team investigated the effects of a single treatment of extracorporeal cytokine removal with CytoSorb therapy, in addition to the standard treatments including, for example antibiotics, applied in patients with early stage septic shock (within the first 24 hours after onset of septic shock or after ICU admission). Twenty patients were randomized into a group treated with the CytoSorb therapy (n=10) for 24 hours or a control group (n=10). Clinical and laboratory data was recorded at the baseline and after 12, 24 and 48 hours.

The results show a significant decrease of Big-endothelin 1 (which is involved in the pathologic changes of the vascular system), procalcitonin (PCT) (an important marker of inflammation) and most importantly, norepinephrine doses needed to maintain sufficient cardio-vascular function – a vaso-constructive drug which is supposed to stabilize blood pressure but on the other hand reduces important oxygen supply to tissues as a side effect. The required norepinephrine doses dropped by almost 70% from baseline within 48 hours, in comparison to the group without CytoSorb. This result represents an important improvement for the patients.

The findings of this study demonstrate also that the most profound effects of CytoSorb therapy can take place in the first 12 hours of the treatment and the CytoSorb application could be tailored to the patients“ individual response and clinical course. However, different therapy doses might be useful for the patient, i.e., more than one CytoSorb treatment may be beneficial depending on the clinical situation.

Quotes:
„Our results could serve as important milestones in designing future studies,“ said Professor Zsolt Molnar, the leading author of the study. „An important aspect in the design of this trial was our pragmatic approach, specifically, using only one adsorber per treated patient and the relatively short 48 hour observation period. Our target was to test the hypothesis that cytokine removal could have almost immediate effect on organ dysfunction and inflammatory response. This goal has been reached. In future, we can investigate which is the most sufficient CytoSorb dosage for the individual patient to provide the best personalized care.“

„We are pleased to learn about the final results of Professor Molnar and his team“s pilot study on treating refractory septic shock patients with CytoSorb therapy as a standalone hemoperfusion treatment before the onset of kidney dysfunction,“ said Dr. Jörg Scheier, Senior Medical Director Europe at CytoSorbents. „Professor Molnar“s work provides a significant contribution to the scientific evidence needed to demonstrate the treatment benefits of CytoSorb therapy and, at the same time the results will also be of great help in designing future, larger randomized multi centric trials with an even better definition of optimal patient characteristics and treatment modalities to maximize Cytosorb therapy effects.“

About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in new technologies and therapies in intelligent blood purification. CytoSorbents Europe GmbH is a hundred percent daughter company of CytoSorbents Corporation and coordinates the introduction and commercialization of CytoSorbents products worldwide.
Its flagship product, CytoSorb® is the first specifically-approved extracorporeal cytokine absorber in the European Union and it is distributed in more than 50 countries worldwide. CytoSorb was designed to reduce the „cytokine storm“ or „cytokine release syndrome,“ which is a major element of the deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. CytoSorbents“ purification technologies are based on biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. CytoSorb has been used in more than 56,000 human treatments to date.

CytoSorbents technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others.

For more information, please visit the Company“s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Company-Contact
Cytosorbents
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Press
Lucy Turpin Communications GmbH
Eva Hildebrandt
Prinzregentenstr. 89
81675 München
Phone: +49 89 41 77 61 -14
E-Mail: cytosorbents@lucyturpin.com
Url: http://www.lucyturpin.com

Medicine Wellness Health

healthbank joins 4Generations Project at Elementa Day School Neuheim

4Generations is an intergenerational project involving students, innovative technology companies and the elderly

healthbank joins 4Generations Project at Elementa Day School Neuheim

4Generations Project

healthbank, a cooperative organization that offers a safe, secure and compliant ecosystem to store, manage and exchange personal health data, is announcing that it is participating in the 4Generations project at Elementa Day School in Neuheim, Switzerland.

4Generations is an intergenerational project involving students in levels 5 and 6, innovative technology companies and the elderly. The project is supported by Generation 65 Plus and helps students learn modern skills such as programming, while also giving the elderly an opportunity to learn from youth about the latest innovations.

„There is a shortage of skilled workers in the information, communications, and technology (ICT) sector and we believe that to counteract this we should start educating students about these topics early,“ said Monica Roth, CEO of Elementa Day School.

„With technology advancing so quickly, it“s easy for people to fall behind if they do not make a true effort to understand all the fantastic tools that we have available to us today. healthbank is proud to be participating in this great initiative,“ said Daniela Gunz, Director of Research Partnerships for healthbank. „All of the technologies that were selected for this project are truly making people“s lives better and opening up new opportunities for those in the later stages of life to lead their lives more autonomously.“

The number of people in the world over the age of 60 is expected to more than double by 2050 and more than triple by 2100. This means that 962 million individuals in 2017 could grow to as much as 3.1 billion by 2100.

„We asked healthbank to join the project because the product can help people to live a better life. Health costs are growing and more and more people living longer,“ explains Ulrike Liebert, CEO of Generation 65 Plus. „This and other factors are having a tremendous impact on the cost of healthcare, but technology is enabling us to better overcome these challenges.“ Throughout the world, living independently in the later stages of life is becoming increasingly prelevant.

healthbank enables users to own and control their own health records while providing continuity in record data that is not always possible with traditional, siloed or paper-based systems. Health data can also be integrated from multiple sources, including from wearable technology into the total picture of health.

„The main stakeholder, the patient, normally has no active role in how their health data is managed. We are changing this – and we believe that the older generations should also be empowered with these kinds of tools,“ added Daniela Gunz.

Press contact healthbank
healthbank innovation AG
Pauline Geniets
Blegistrasse 17a, CH-6340 Baar
Tel. +41 (0) 41 552 24 00
press@healthbank.coop

generation65plus.com
Generation 65 Plus develops concepts on the basis of existing solutions that measurably help people in the third phase of life to live longer autonomously and self-determinedly. In doing so, the company accesses innovations that are at the market entry stage. The strength lies in the integration of all relevant stakeholders, which in some projects means that people from all 4 phases of life are involved. Generation 65 Plus is based in Switzerland but is active throughout Europe, not least due to its active membership in the network of the European Innovation Partnership of Active and Healthy Aging and the continuous exchange with the European AAL programme.

Ulrike Liebert
0041 79 28 79 755
ulrike.liebert@generation65plus.com

Über healthbank
healthbank ist die weltweit erste bürgereigene, neutrale und unabhängige Gesundheitsdaten-Transaktionsplattform, die es Menschen ermöglicht, ihre Daten auf sichere und datenschutzkonforme Art und Weise mit anderen Partnern zu teilen. healthbank verbindet Datenquellen aller Art aus dem gesamten Gesundheitsbereich und belohnt Teilnehmer, ihre Gesund-heitsdaten für Forschungszwecke zu teilen. Mit Sitz in der Schweiz steht healthbank für schweizerische Neutralität, Ver-trauen und Datenschutz und ermöglicht es den teilnehmenden Bürgern, Forschern und Organisationen mit grossen Daten-mengen sich miteinander zu vernetzen. Damit kann der Wert von Gesundheits- und medizinischen Daten auf dieser unab-hängigen, globalen Gesundheitsplattform optimal erschlossen werden. healthbank fördert Innovationen im Gesundheits-wesen, von der Prävention bis zur Heilung, zu einem angemesseneren Preis und besserer Qualität für das Wohl des Ein-zelnen und der Gesellschaft. www.healthbank.coop

Contact
healthbank
Pauline Geniets
Blegistrasse 17a
6340 Baar
Phone: +41 44 202 61 60
E-Mail: press@healthbank.coop
Url: http://www.healthbank.coop